SpaceX-Linked Stock Momentus Is Rocketing Higher: What’s Going On?

Momentus Inc (NASDAQ: MNTS) shares are trading higher Thursday after the company signed a contract with FOSSA systems to place its satellites into low-Earth orbit<

Momentus Inc (NASDAQ:MNTS) shares are trading higher Thursday after the company signed a contract with FOSSA systems to place its satellites into low-Earth orbit.

What To Know: Momentus will launch FOSSA’s satellites as part of two Vigoride Orbital Service Vehicle missions starting in 2023.

The first group of satellites will be launched on the SpaceX Transporter-8 mission no earlier than June. The mission will act as a demonstration for a second batch of satellites expected to launch onboard a follow-on Vigoride vehicle on a later SpaceX Transporter mission.

“FOSSA Systems flew with us on our inaugural mission that launched in May 2022. We’re pleased to have earned their trust in selecting us as their space transportation provider for their new satellites, and we look forward to building a long-term partnership toward our first large-scale constellation deployment,” said John Rood, CEO of Momentus.

Momentus is a U.S.-based commercial space company that offers transportation and other in-space infrastructure services. The company signed multiple launch agreements with Elon Musk’s SpaceX in mid-2022. 

Check This Out: Elon Musk’s SpaceX Raising $750M In Fresh Funding Round Led By a16z: Report

MNTS Price Action: Momentus shares are up 25.4% at $1.14 at the time of writing, according to Benzinga Pro.

Photo: courtesy of SpaceX.

Total
0
Shares
Related Posts
Read More

Most Of Crypto ‘Still Junk,’ JPMorgan Blockchain Head Says — Despite Bank’s Increased Interest In DeFi

JPMorgan's head of blockchain believes that most cryptocurrencies have a short lifespan.  What Happened: Umar Farooq, CEO of JPMorgan’s blockchain unit Onyx, talked at a seminar hosted by the Monetary Authority of Singapore on Monday about the implications of lagging cryptocurrency regulations. 

$MANA

Read More

Aura Biosciences To Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma At AAO 2023

Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that updated data from

AURA